# Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

> **NCT03278873** · — · TERMINATED · sponsor: **MeiraGTx UK II Ltd** · enrollment: 34 (actual)

## Conditions studied

- Achromatopsia

## Interventions

- **BIOLOGICAL:** Prior exposure to AAV-CNGA3 or AAV-CNGB3

## Key facts

- **NCT ID:** NCT03278873
- **Lead sponsor:** MeiraGTx UK II Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-29
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-04-04
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Strategic decision to not further develop AAV8-hCARp.hCNGB3 and AAV8-hG1.7p.coCNGA3. The decision is not due to safety concerns.
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278873, "Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03278873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*